Answers are grounded in this paper and cite their sources.
AIMS: To estimate the concurrent positivity of claudin 18 isoform 2 (CLDN18.2) and programmed death-ligand 1 (PD-L1), and their cross-sectional association, in gastric and gastroesophageal junction adenocarcinoma. MATERIALS & METHODS: PubMed, Embase, Web of Science Core Collection, SinoMed, and Google Scholar were searched. Concurrent positivity at PD-L1 combined positive score (CPS) thresholds ≥1, ≥5, and ≥10 was pooled using random-effects models; associations were summarized as odds ratios (ORs). Risk of bias was assessed with Joanna Briggs Institute (JBI) tools. RESULTS: Forty-five reports were included; 37 provided quantitative data. Twelve, 10, and four studies contributed to CPS ≥1, ≥5, and ≥10 models, respectively. Pooled prevalence (95% confidence interval [CI]; 95% prediction interval [PI]) was 23.5% (17.3-31.0%; 7.6-53.5%), 15.4% (10.6-21.9%; 4.5-41.3%), and 12.5% (8.1-18.7%; 4.0-32.8%). ORs were 1.03 (0.85-1.26), 1.10 (0.79-1.53), and 1.15 (0.83-1.58); all 95% CIs included 1. CONCLUSIONS: Estimates are averages across heterogeneous settings among patients with results available for both biomarkers; because joint testing was incomplete or selective in some cohorts, these estimates may not represent all patients with the relevant cancers. Different studies contributed at each CPS threshold, and no esophageal-adenocarcinoma-only cohort contributed to the primary analyses.
No takes yet. Share an insight, caveat, or question.
龙柳珍 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: